Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol
Purpose
ADNI3 (Alzheimer's Disease Neuroimaging Initiative 3) is the fourth wave of a North American multicenter observational study launched in 2004, sponsored by the National Institute on Aging and the National Institutes of Health. The primary goal of this study is to discover, optimize, standardize, and validate clinical biomarkers used in Alzheimer's disease research and clinical trials. This study seeks to enroll individuals ages 55-90, willing and able to undergo yearly test procedures including cognitive tests, questionnaires, brain imaging, blood draws, and spinal taps. Eligible individuals may have normal cognition with no memory concerns, or have memory concerns and diagnosis of mild cognitive impairment or dementia due to Alzheimer’s disease. Participants will be evaluated on a yearly basis, for 2 to 4 years. To learn more, please call Celine Ossinalde at (310) 794-6191 or send an email to: This email address is being protected from spambots. You need JavaScript enabled to view it.. (PI: Sarah Kremen, MD, Easton Center's Katherine and Benjamin Kagan Alzheimer's Disease Treatment Dev. Program)
| Sponsor: | University of Southern California |
| ClinicalTrials.gov Identifier: | NCT02854033 |
| Condition: |
| Mild Cognitive Impairment (MCI) Alzheimer's Disease (AD) |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol |
| Length of Study: | Participants will be evaluated on a yearly basis, for 2 to 4 years. |
Eligibility
| Ages Eligible for Study: | 55 Years to 90 Years |
| Genders Eligible for Study: | Both |
Contact: Celine Ossinalde at (310) 794-6191 or This email address is being protected from spambots. You need JavaScript enabled to view it. to participate in this study or for more information.